Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Atopaxar (Primary)
- Indications Coronary thrombosis
- Focus Adverse reactions
- Acronyms E555G000-201; LANCELOT-CAD
- Sponsors Eisai Co Ltd
- 27 Mar 2012 Biomarker results presented at the 61st Annual Scientific Session of the American College of Cardiology.
- 09 Sep 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 09 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.